



ACCUSTEM

Building Better Oncology Tools



ACCUSTEM

DISCLAIMER

This presentation contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this presentation are forward-looking statements. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. In some cases, you can identify these forward-looking statements by terms such as "anticipate," "believe," "continue," "could," "depends," "estimate," "expects," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short-term and long-term business operations and objectives and financial needs.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from those anticipated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation. These forward-looking statements speak only as of the date of this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason.

COMPANY OVERVIEW



Our mission at AccuStem is to provide proprietary diagnostic tools that address unanswered clinical questions and have therapeutic-like market and margin opportunities

As the only known company evaluating tumor “stemness,” our initial focus will be the commercialization of StemPrintER in the more than \$1.3B breast cancer market

Our data suggest StemPrintER may direct the surgical approach for women with breast cancer¹

- Identifying the ideal type of surgery addresses an unmet clinical need that could improve outcomes and reduce healthcare costs

1. Data on file

ACCUSTEM ROADMAP TO COMMERCIALIZATION

Our focus is commercializing a proprietary genomic test in breast cancer representing an estimated market opportunity greater than \$1.3B annually that does not require FDA clearance

ASSET	TARGET CANCER MARKET	PHASE 1 (ANALYTICAL VALIDATION)	PHASE 2 (CLINICAL VALIDATION)	PHASE 3 (CLINICAL UTILITY)	CMS COVERAGE
StemPrintER	Early Stage Breast Cancer				*may meet minimum threshold
StemPrintER	Early Stage Lung Cancer				
	Localized Prostate Cancer				

ACCUSTEM AT A GLANCE

BREAST CANCER PROGRAM

- In-licensed StemPrintER assay from Istituto Europeo di Oncologia (IEO)
- US and EU patents approved
- Established collaborations with leading US and EU institutions
- Our assay has been validated in prospective patient cohorts
- Preparing for submission of data for new indication to SABCS
- Planning to address unanswered clinical questions with our assay

STEMNESS PROGRAM

- Planning to build on current research of stemness across different tumor types
- Pursuing signal seeking in lung and prostate cancers
- Clinical questions identified via work with lung and prostate KOLs
- StemPrintER evaluated in a Cancer Genome Atlas lung cancer cohort
- Where applicable, commodity testing will be offered along with StemPrintER

EFFICIENT CORPORATE EXECUTION

- Proven leadership team with nearly 60 combined years of experience in the oncology diagnostics sector
- Opening research lab to focus on breast and stemness programs
- Planning to expand product offering to additional tumor types as resources permit
- Evaluating collaboration strategies with industry partners
- Forming SAB to support effective product development

THE ROLE OF “STEMNESS” IN CANCER



Article | Open Access | Published: 27 October 2020

Assessing the prognostic value of stemness-related genes in breast cancer patients

Wen-Jie Wang, Han Wang, Meng-sen Wang, Yue-Qing Huang, Yu-Yuan Ma, Jie Qi, Jian-Ping Shi & Wei Li

The cancer stem cell hypothesis is a fundamental concept in cancer biology

- Essentially, all tumors arise from precursor cells that are similar to stem cells; these cancer stem cells are highly adaptable and have the ability to grow indefinitely
- This hypothesis and tumor “stemness” have been widely studied across a multitude of tumor types

“Stemness” indicates how much a tumor behaves like stem cells

- “High stemness” in tumors is considered a primary rationale for disease recurrence and/or lack of response to chemotherapy and radiation
- Surgery may be the only way to effectively kill cancer stem cells or “high stemness” tumors

The Role of Cancer Stem Cells in Radiation Resistance



Christoph Reinhold Arnold^{1*}, Julian Mangesius¹, Ira-Ida Skvortsova^{1,2} and Ute Ganswindt¹

Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance

Sangita Sridharan^{1†}, Cory M. Howard^{1†}, Augustus M. C. Tilley^{1†}, Boopathi Subramaniyan^{1†}, Amit K. Tiwari², Randall J. Ruch¹ and Dayanidhi Raman^{1*}

While the medical community recognizes the potential utility of measuring tumor “stemness,” existing diagnostic approaches have not been able to accurately assess it in patients

VALIDATION OF STEMPRINTER IN BREAST CANCER



1. Pece, et al. Ebiomedicine. 2019; 2. Pece, et al. Eur J Cancer. 2022

CLINICAL DECISION MAKING IN BREAST CANCER

BIOPSY

Clinical Questions

What is the subtype of cancer?
Is patient a candidate for NAC?
How aggressive is the cancer?

**BREAST CANCER
GENOMICS**

SURGERY

Mastectomy vs. lumpectomy?
Sentinel node vs. full axillary
dissection?

 ACCUSTEM

THERAPY

Adjuvant Chemotherapy?
Hormone Therapy?
Radiation Therapy?

 ACCUSTEM

 Myriad
genetics

 AGENDIA

 EXACT
SCIENCES

 HOLOGIC
The Science of Care

 veracyte

 ACCUSTEM

BREAST CANCER GENOMICS INDUSTRY

	AccuStem	Exact Sciences	Agendia	Hologic	Myriad Genetics	Veracyte
Product	StemPrintER	OncotypeDX	MammaPrint	Breast Cancer Index	Endopredict	Prosigna
Global Serviceable Market	798,000	562,000	562,000	562,000	562,000	562,000
Reimbursement (CMS)	N/A	\$3873	\$3873	\$3873	\$3873	\$3873
2021 Revenue	N/A	\$600M ¹	\$60M	\$37M	~\$16M ²	~\$12M ³
Market Cap	\$16.44M	\$12.27B	N/A (private)	\$19.16B	\$2.02B	\$1.97B
Risk of Recurrence	Yes	Yes	Yes	Yes	Yes	Yes
Adjuvant Chemo	Yes	Yes	Yes	Yes	Yes	Yes
Surgery Type	Yes	No	No	No	No	No

1. Estimated global serviceable market based on 2015 data; 2. Full precision medicine division revenue (many products, not just OncotypeDX); EndoPredict revenue was \$4.1M for Q1 2021; Prosigna revenue was \$3.1M for Q1 2021

ACCUSTEM AT A GLANCE

BREAST CANCER PROGRAM	STEMNESS PROGRAM	EFFICIENT CORPORATE EXECUTION
<ul style="list-style-type: none">• In-licensed StemPrintER assay from Istituto Europeo di Oncologia (IEO)• US and EU patents approved• Established collaborations with leading US and EU institutions• Our assay has been validated in prospective patient cohorts• Preparing for submission of data for new indication to SABCS• Planning to address unanswered clinical questions	<ul style="list-style-type: none">• Planning to build on current research of stemness across different tumor types• Pursuing signal seeking in lung and prostate cancers• Clinical questions identified via work with lung and prostate KOLs• StemPrintER evaluated in a Cancer Genome Atlas lung cancer cohort• Where applicable, commodity testing will be offered along with StemPrintER	<ul style="list-style-type: none">• Proven leadership team with nearly 60 combined years of experience in the oncology diagnostics sector• Opening research lab to focus on breast and stemness programs• Planning to expand product offering to additional tumor types as resources permit• Evaluating collaboration strategies with industry partners• Forming SAB to support effective product development

OPPORTUNITY IN LUNG CANCER

2M+ new lung cancer diagnoses annually

- No genomic tests to inform surgical approach, benefit of radiation

StemPrintER may inform treatment planning in patients with early stage lung cancer

- By evaluating the underlying "stem" biology of tumors, we believe our test will address unanswered clinical questions

	AccuStem	Oncocyte
Product	StemPrintER	DetermaRx
Global Serviceable Market	416,000	416,000
Reimbursement (CMS)	N/A	\$3150
Risk of Recurrence	Yes	Yes
Surgery vs. Stereotactic Body Radiotherapy (SBRT)	Yes	No

OPPORTUNITY IN PROSTATE CANCER

1.4M+ new prostate cancer diagnoses annually

- No genomic tests to inform approach to definitive treatment (e.g., surgery, radiation, ablation)

StemPrintER may inform treatment planning in patients with localized prostate cancer

- By evaluating the underlying "stem" biology of tumors, we believe our test will address unanswered clinical questions

	AccuStem	MDxHealth	Myriad Genetics	Veracyte
Product	StemPrintER	OncotypeDX	Prolaris	Decipher Prostate Biopsy
Global Serviceable Market	427,000	54,000	1,570,000	314,000
Reimbursement (CMS)	N/A	\$4000	\$3400	\$3800
Risk of Recurrence	Yes	Yes	Yes	Yes
Active Surveillance vs. Definitive Treatment	Yes	Yes	Yes	Yes
Type of Definitive Treatment	Yes	No	No	No

ACCUSTEM AT A GLANCE

BREAST CANCER PROGRAM	STEMNESS PROGRAM	EFFICIENT CORPORATE EXECUTION
<ul style="list-style-type: none">• In-licensed StemPrintER assay from Istituto Europeo di Oncologia (IEO)• US and EU patents approved• Established collaborations with leading US and EU institutions• Our assay has been validated in prospective patient cohorts• Preparing for submission of data for new indication to SABCS• Planning to address unanswered clinical questions with StemPrintER	<ul style="list-style-type: none">• Planning to build on current research of stemness across different tumor types• Pursuing signal seeking in lung and prostate cancers• Clinical questions identified via work with lung and prostate KOLs• StemPrintER evaluated in a Cancer Genome Atlas lung cancer cohort• Where applicable, commodity reagents will be replaced with StemPrintER	<ul style="list-style-type: none">• Proven leadership team with nearly 60 combined years of experience in the oncology diagnostics sector• Opening research lab to focus on breast and stemness programs• Planning to expand product offering to additional tumor types as resources permit• Evaluating collaboration strategies with industry partners• Forming SAB to support effective product development

OUR LEADERSHIP TEAM AND APPROACH: A PROVEN TRACK RECORD

WENDY BLOSSER, CEO


- ✓ 23 years of success building organizations in Oncology and Women's Health
- ✓ Led sales at Genzyme Genetics prior to \$925M acquisition by Integrated Oncology (ticker: LH)
- ✓ Cytoc leadership prior to \$6.2B Hologic acquisition

KEEREN SHAH, CFO

- ✓ 20 years of experience in controllership, financial planning and analysis and IPO offerings
- ✓ Held variety of finance roles at Visa, Arthur Andersen, BBC Worldwide, Tiziana Life Sciences and Okyo Pharma

JOE FLANAGAN, CBO

- ✓ 15 years of strategic expertise with successful product launches at early-stage diagnostic start ups
- ✓ Drove revenue growth at Biodesix, Agendia, Ambry and PTI by enhancing sales team clinical agility and logistical processes



INVESTMENT AND COMPANY HIGHLIGHTS

- ✓ Management team with wide-ranging leadership experience across various functional areas, deep relationships with luminary US institutions and a track record of successful launch/relaunch strategies
- ✓ Only known company with novel diagnostic platform evaluating tumor “stemness” with potential utility across a broad spectrum of tumor types
- ✓ Strong foundation of evidence for StemPrintER in breast cancer, including outperformance of current market leader, supporting commercialization in \$1.3B market
- ✓ Building body of evidence that we believe makes AccuStem a strong acquisition target for healthcare companies



THANK YOU FOR YOUR
CONSIDERATION



Info@Accustem.com

| Accustem.com